

*For Immediate Release:
January 3, 2005
Cambridge, MA*

*Contact:
Bill Hayden, Senior Vice President
514-895-2455
bill@coalesix.com*

Coalesix Announces Appointment of James H Wikel as Chief Technology Officer

(January 3, 2005, Cambridge, MA) -- Continuing its mission to improve the efficiency of drug discovery, Coalesix today named James H. Wikel as its Chief Technology Officer, where he will serve to help bring together the theories of computational chemistry with the practical applications of medicinal chemistry.

Wikel joins Coalesix after a 33-year career with Eli Lilly & Company, where he emerged as one of the most respected figures in discovery chemistry. During his three decades at Eli Lilly, Wikel guided many of the company's pioneering initiatives in applying computational technology to drug discovery.

"We are absolutely delighted to have an individual of Jim's capability, experience and vision as part of our leadership team," said Paul Edwards, Coalesix President and CEO. "With his first-hand knowledge of the trials and tribulations that are part of both computational and medicinal chemistry, we are confident that Jim's experience can guide us towards an innovative environment and the production of a new approach to Drug Candidate design."

In accepting his new role, Wikel said he hopes to help Coalesix unleash the power of new computational approaches while also incorporating the important aspects of human intuition and lab experience. "The Coalesix environment offers a way of capturing and mutually reinforcing the best of what computational and medicinal chemistry have to offer. I look forward to developing the Coalesix environment so that it can make a lasting impact on the economics and efficiency of drug discovery."

Headquartered in Cambridge, MA, Coalesix focuses on the development and commercialization of technology to improve the efficiency of drug discovery through the use of its *Mobius* Candidate Design Environment (CDE). *Mobius* offers drug discovery organization the ability to maximize the return on all of their Lead optimization efforts and resources while at the same time helping overcome the lead-to-candidate bottleneck.

The *Mobius* CDE fosters interactions between computational and medicinal chemistry to produce a novel approach to address the challenges of Lead Optimization in order to enable faster identification of more potential drug candidates.

More information on Coalesix and the *Mobius* CDE can be obtained by contacting Bill Hayden, Senior Vice President, at 514-895-2455 or bill@coalesix.com